Filtered By:
Drug: Temodar
Therapy: Radiation Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 62 results found since Jan 2013.
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
CONCLUSION: The INSIGhT design enabled efficient simultaneous testing of three experimental agents using a shared control arm and adaptive randomization. Two investigational arms had superior PFS compared with the control arm, but none demonstrated an OS benefit. The INSIGhT design may promote improved and more efficient therapeutic discovery in glioblastoma. New arms have been added to the trial.PMID:37722087 | DOI:10.1200/JCO.23.00493
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Rifaquat Rahman Lorenzo Trippa Eudocia Q Lee Isabel Arrillaga-Romany Geoffrey Fell Mehdi Touat Christine McCluskey Jennifer Wiley Sarah Gaffey Jan Drappatz Mary R Welch Evanthia Galanis Manmeet S Ahluwalia Howard Colman L Burt Nabors Jaroslaw Hepel Heinri Source Type: research
A pilot phase Ib study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wild-type glioblastoma
CONCLUSIONS: Concurrent tadalafil is well tolerated during chemoradiotherapy for GBM. Tadalafil is associated with a reduction of peripheral MDSCs after chemoradiotherapy and increased CD8 T-cell proliferation and activation.PMID:37554225 | PMC:PMC10406429 | DOI:10.1093/noajnl/vdad088
Source: Cancer Control - August 9, 2023 Category: Cancer & Oncology Authors: Subhajit Ghosh Tanner M Johanns Milan G Chheda Eric Liu Omar Butt Christopher Abraham Shahed Badiyan Yi Huang David DeNardo Albert H Kim Dennis Hallahan Dinesh Thotala Jiayi Huang Source Type: research
Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression
CONCLUSIONS: High NLR is associated with worse outcomes in newly diagnosed and recurrent glioblastoma. Appropriate eligibility criteria and accounting and reporting of blood-based biomarkers are important in the design and interpretation of newly diagnosed and recurrent glioblastoma trials.PMID:37554224 | PMC:PMC10406420 | DOI:10.1093/noajnl/vdad083
Source: Adv Data - August 9, 2023 Category: Epidemiology Authors: Davy Deng Lubna Hammoudeh Gilbert Youssef Yu-Hui Chen Kee-Young Shin Mary Jane Lim-Fat Jose Ricardo McFaline-Figueroa Ugonma N Chukwueke Shyam Tanguturi David A Reardon Eudocia Q Lee Lakshmi Nayak Wenya Linda Bi Omar Arnaout Keith L Ligon Patrick Y Wen Ri Source Type: research
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy
Biomed Pharmacother. 2023 Jul 15;165:115174. doi: 10.1016/j.biopha.2023.115174. Online ahead of print.ABSTRACTGlioblastoma (GBL) is the most common (60-70% of primary brain tumours) and the most malignant of the glial tumours. Although current therapies remain palliative, they have been proven to prolong overall survival. Within an optimal treatment regimen (incl. surgical resection, radiation therapy, and chemotherapy) temozolomide as the current anti-GBL first-line chemotherapeutic has increased the median overall survival to 14-15 months, and the percentage of patients alive at two years has been reported to rise from 1...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 17, 2023 Category: Drugs & Pharmacology Authors: Aleksandra Krajcer Ewelina Grzywna Joanna Lewandowska- Łańcucka Source Type: research
Radiation Therapies in Cancer
Cancer Treat Res. 2023;185:59-77. doi: 10.1007/978-3-031-27156-4_4.ABSTRACTA crucial element of cancer treatment is radiation therapy that is used to destroy tumors and cancer cells through radiation. Another essential component is immunotherapy that helps immune system to combat cancer. The combination of both radiation therapy and immunotherapy is being focused recently for the treatment of many tumors. Chemotherapy includes the use of some chemical agent to control the growth of cancer, whereas irradiation involves the use of radiations of high energy to kill cancer cells. The union of both became the strongest practice...
Source: Cancer Control - June 12, 2023 Category: Cancer & Oncology Authors: Muhammad Rizwan Tariq Shinawar Waseem Ali Noor Fatima Aqsa Jabeen Asma Saleem Qazi Amna Hameed Waseem Safdar Source Type: research
Molecules, Vol. 28, Pages 3809: Acetogenins-Rich Fractions of Annona coriacea Suppress Human Glioblastoma Viability and Migration by Regulating Necroptosis and MMP-2 Activity In Vitro
. M. A. Ribeiro
Glioblastoma (GBM) is an incurable primary brain tumor with a poor prognosis. Resection, radiation therapy, and temozolomide (TMZ) are insufficient to increase survival, making the treatment limited. Thus, the search for more effective and specific treatments is essential, making plants a promising source for elucidating new anti-glioblastoma compounds. Accordingly, this study investigated the effects of four fractions of hexane and ethyl acetate extract of Annona coriacea Mart., enriched with acetogenins, against GBM cell lines. All four fractions were selectively cytotoxic to GBM cells when compared t...
Source: Molecules - April 29, 2023 Category: Chemistry Authors: Lorena R. Sousa Ana Gabriela S. Oliveira Ant ônio Arantes Jo ão Gabriel M. Junqueira Gerso P. Alexandre Vanessa G. P. Severino Rui Manuel Reis Bonglee Kim Rosy I. M. A. Ribeiro Tags: Article Source Type: research
Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature
ConclusionHF-RT may offer equivalent outcomes and reduce treatment burden compared to CF-RT in young, fit GBM patients.
Source: Journal of Neuro-Oncology - November 10, 2022 Category: Cancer & Oncology Source Type: research
Imaging Findings of < sup > 18 < /sup > F-Choline and < sup > 18 < /sup > F-DOPA PET/MRI in a Case of Glioblastoma Multiforme Pseudoprogression: Correlation with Clinical Outcome
We describe the case of 74-year-old-male, previously treated with fronto-parietal craniotomy due to primary glioblastoma multiforme (GBM), followed by concurrent radiation therapy (RT) and temozolomide (TMZ) chemotherapy. Magnetic resonance imaging (MRI) of the brain, at 1 month after completing RT + TMZ, depicted partial response. Three months later, the patient was submitted to a further brain MRI, that resulted doubtful for therapy induced changes (i.e., pseudoprogression). The patient, who had been previously treated with prostatectomy for prostate cancer (PC), underwent a positron emission tomography/computed tomograp...
Source: Molecular Medicine - October 31, 2022 Category: Molecular Biology Authors: Luca Filippi Angela Spanu Oreste Bagni Orazio Schillaci Barbara Palumbo Source Type: research
Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
Front Oncol. 2022 Sep 27;12:888100. doi: 10.3389/fonc.2022.888100. eCollection 2022.ABSTRACTGlioblastoma multiforme (GBM) is at present an incurable disease with a 5-year survival rate of 5.5%, despite improvements in treatment modalities such as surgery, radiation therapy, chemotherapy [e.g., temozolomide (TMZ)], and targeted therapy [e.g., the antiangiogenic agent bevacizumab (BEV)]. Diffusing alpha-emitters radiation therapy (DaRT) is a new modality that employs radium-224-loaded seeds that disperse alpha-emitting atoms inside the tumor. This treatment was shown to be effective in mice bearing human-derived GBM tumors. ...
Source: Cancer Control - October 14, 2022 Category: Cancer & Oncology Authors: Yossi Nishri Maayan Vatarescu Ishai Luz Lior Epstein Mirta Duman čić Sara Del Mare Amit Shai Michael Schmidt Lisa Deutsch Robert B Den Itzhak Kelson Yona Keisari Lior Arazi Tomer Cooks Vered Domankevich Source Type: research
Current therapeutic options for glioblastoma and future perspectives
Expert Opin Pharmacother. 2022 Sep 13. doi: 10.1080/14656566.2022.2125302. Online ahead of print.ABSTRACTINTRODUCTION: Glioblastoma is a malignant primary brain tumor that affects approximately 250,000 new patients per year worldwide. It is among the most difficult cancers to treat, and 5-year survival rates remain low. Standard therapies for glioblastoma include surgical resection, radiation therapy and systemic chemotherapy. Multiple clinical trials are currently underway to improve therapeutic options for glioblastoma patients.AREAS COVERED: We conducted a search of the literature on therapeutic options for glioblastoma...
Source: Expert Opinion on Pharmacotherapy - September 14, 2022 Category: Drugs & Pharmacology Authors: Elisa Aquilanti Patrick Y Wen Source Type: research
Treatment of Prolactinoma
Medicina (Kaunas). 2022 Aug 13;58(8):1095. doi: 10.3390/medicina58081095.ABSTRACTProlactinomas are the commonest form of pituitary neuroendocrine tumor (PitNET), representing approximately half of such tumors. Dopamine agonists (DAs) have traditionally been the primary treatment for the majority of prolactinomas, with surgery considered the second line. The aim of this review is to examine the historical and modern management of prolactinomas, including medical therapy with DAs, transsphenoidal surgery, and multimodality therapy for the treatment of aggressive prolactinomas and metastatic PitNETs, with an emphasis on the e...
Source: Medicina (Kaunas) - August 26, 2022 Category: Universities & Medical Training Authors: Warrick J Inder Christina Jang Source Type: research
